Investigational Drug Details
| Drug ID: | D281 |
| Drug Name: | Prebiotic |
| Synonyms: | -- |
| Type: | Supplement |
| DrugBank ID: | -- |
| DrugBank Description: | -- |
| PubChem ID: | -- |
| CasNo: | -- |
| Repositioning for NAFLD: | No |
| SMILES: | -- |
| InChiKey: | -- |
| Molecular Weight: | -- |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | -- |
| Therapeutic Category: | -- |
| Clinical Trial Progress: | Clinical trial completed (NCT03184376: Independent of other lifestyle changes, prebiotic supplementation reduced histologically-confirmed steatosis in patients with NASH. Larger follow-up studies are warranted.) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0617 | IRCT201410052394N13 | Phase 2 | Not Recruiting | No Results Available | 14/12/2014 | 22 February 2018 | Details |
| L0635 | IRCT201301223140N6 | Phase 2 | Not Recruiting | No Results Available | 16/01/2014 | 22 February 2018 | Details |
| L0684 | NCT00870012 | Not applicable | Not recruiting | No Results Available | 25/03/2009 | 19 February 2015 | Details |
| L0727 | NCT04130321 | Not applicable | Not recruiting | No Results Available | 03/10/2019 | 7 September 2021 | Details |
| L0776 | SLCTR/2018/042 | Phase 0 | Recruiting | No Results Available | 31/12/2018 | 7 February 2022 | Details |
| L0819 | NCT03184376 | Not applicable | Not recruiting | No Results Available | 08/06/2017 | 16 December 2017 | Details |
| L0858 | NCT02642172 | Not applicable | Not recruiting | No Results Available | 13/12/2015 | 13 September 2021 | Details |
| L0865 | NCT02568605 | Not applicable | Not recruiting | No Results Available | 30/09/2015 | 10 May 2021 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00025 | 35251100 | Front Plant Sci | Raffinose Family Oligosaccharides: Friend or Foe for Human and Plant Health? | Details |
| A00113 | 35216439 | Int J Mol Sci | Heat-Inactivated Akkermansia muciniphila Improves Gut Permeability but Does Not Prevent Development of Non-Alcoholic Steatohepatitis in Diet-Induced Obese Ldlr-/-.Leiden Mice. | Details |
| A00392 | 35103461 | Minerva Endocrinol (Torino) | Akkermansia muciniphila as a novel powerful bacterial player in the treatment of metabolic disorders. | Details |
| A00515 | 35055177 | Int J Mol Sci | Inulin Improves Diet-Induced Hepatic Steatosis and Increases Intestinal Akkermansia Genus Level. | Details |
| A00526 | 35053205 | Biomolecules | Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives. | Details |
| A00758 | 34978141 | Obes Rev | Human microbiome and metabolic health: An overview of systematic reviews. | Details |
| A01446 | 34742934 | Arch Biochem Biophys | The probiotic effects of AB23A on high-fat-diet-induced non-alcoholic fatty liver disease in mice may be associated with suppressing the serum levels of lipopolysaccharides and branched-chain amino acids. | Details |
| A01474 | 34734433 | J Gastroenterol Hepatol | New perspective on fecal microbiota transplantation in liver diseases. | Details |
| A01475 | 34734369 | J Gastrointest Surg | The Role of Gut-Derived Lipopolysaccharides and the Intestinal Barrier in Fatty Liver Diseases. | Details |
| A01731 | 34634561 | Biomed Pharmacother | Jaboticaba (Myrciaria jaboticaba) powder consumption improves the metabolic profile and regulates gut microbiome composition in high-fat diet-fed mice. | Details |
| A01838 | 34598315 | Immun Inflamm Dis | Multidirectional facets of obesity management in the metabolic syndrome population after liver transplantation. | Details |
| A01921 | 34561722 | Eur J Nutr | Effects of β-glucan, probiotics, and synbiotics on obesity-associated colitis and hepatic manifestations in C57BL/6J mice. | Details |
| A02013 | 34530928 | Microbiome | Commensal microbe-derived acetate suppresses NAFLD/NASH development via hepatic FFAR2 signalling in mice. | Details |
| A02045 | 34521466 | Trials | Effect of Lycium barbarum polysaccharide supplementation in non-alcoholic fatty liver disease patients: study protocol for a randomized controlled trial. | Details |
| A02082 | 34511051 | Benef Microbes | Probiotic and prebiotic interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis. | Details |
| A02267 | 34441497 | Foods | Probiotics and Prebiotics as a Strategy for Non-Alcoholic Fatty Liver Disease, a Narrative Review. | Details |
| A02471 | 34360773 | Int J Mol Sci | Effect of Microbiome on Non-Alcoholic Fatty Liver Disease and the Role of Probiotics, Prebiotics, and Biogenics. | Details |
| A02491 | 34355155 | JHEP Rep | A dynamic association between myosteatosis and liver stiffness: Results from a prospective interventional study in obese patients. | Details |
| A02533 | 34338703 | Food Funct | Co-supplementation of camelina oil and a prebiotic is more effective for in improving cardiometabolic risk factors and mental health in patients with NAFLD: a randomized clinical trial. | Details |
| A02552 | 34330514 | Clin Nutr ESPEN | Contribution of gut microbiota to nonalcoholic fatty liver disease: Pathways of mechanisms. | Details |